Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.
Limited Stage Small Cell Lung Cancer
DRUG: Durvalumab
Progression free survival, The PFS time is defined as time from enrollment to locoregional or systemic, Each 42 days up to intolerance the toxicity or PD (up to 24 months)
OS（Overall Survival）, OS was defined as time from date of enrollment to date of death due to any cause., From enrollment until death (up to 24 months)|Safety analysis, Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 1 year
Primary Outcome Measures:

Progression free survival

Secondary Outcome Measures:

Overall survival Safety analysis